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Abstract
Objective: Vitamin D and fibroblast growth factor-23 (FGF-23) are related with cardiovascular disorders. We have
investigated the relationship of calcidiol (vitamin D metabolite) and FGF-23 plasma levels with the incidence of adverse
outcomes in patients with coronary artery disease.
Methods: Prospective follow-up study of 704 outpatients, attending the departments of Cardiology of four hospitals in
Spain, 6–12 months after an acute coronary event. Baseline calcidiol, FGF-23, parathormone, and phosphate plasma levels
were assessed. The outcome was the development of acute ischemic events (any acute coronary syndrome, stroke, or
transient ischemic attack), heart failure, or death. Cox regression adjusted for the main confounders was performed.
Results: Calcidiol levels showed a moderate-severe decrease in 57.3% of cases. Parathormone, FGF-23, and phosphate levels
were increased in 30.0%, 11.5% and 0.9% of patients, respectively. Only 22.4% of patients had glomerular filtration rate,
60 ml/min1.73 m2. After a mean follow-up was 2.1560.99 years, 77 patients developed the outcome. Calcidiol (hazard ratio
[HR] = 0.67; 95% confidence interval [CI] = 0.48–0.94; p = 0.021) and FGF-23 (HR = 1.13; 95% CI = 1.04–1.23; p = 0.005) plasma
levels predicted independently the outcome. There was a significant interaction between calcidiol and FGF-23 levels
(p = 0.025). When the population was divided according to FGF-23 levels, calcidiol still predicted the outcome
independently in patients with FGF-23 levels higher than the median (HR = 0.50; 95% CI = 0.31–0.80; p = 0.003) but not in
those with FGF-23 levels below this value (HR = 1.03; 95% CI = 0.62–1.71; p = 0.904).
Conclusions: Abnormalities in mineral metabolism are frequent in patients with stable coronary artery disease. In this
population, low calcidiol plasma levels predict an adverse prognosis in the presence of high FGF-23 levels.
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Background
Renal disease is associated with increased cardiovascular risk.
When mild decrements in glomerular filtration rate appear,
phosphate elimination decreases. High phosphate serum levels
have been associated with increased mortality and cardiovascular
events even in the absence of renal disease [1]. Compensatory
responses to maintain phosphate homeostasis include an increase
in fibroblast growth-23 (FGF-23) and a subsequent rise in
parathormone levels [2]. FGF-23 promotes phosphaturia and
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diminishes vitamin D plasma levels, downregulating its synthesis
and enhancing its degradation [2].
Adaptive mechanisms appear before serum phosphate levels are
increased. These mechanisms have also been related to vascular
damage [3,4]. High FGF-23 plasma levels are independently
associated with endothelial dysfunction, arterial stiffness, left
ventricular hypertrophy, progression of renal disease, incidence
of mortality and cardiovascular events [3,4]. Vitamin D deficiency
has been associated with hypertension, coronary artery disease
(CAD) and stroke [5,6]. In addition, vitamin D attenuates left
ventricular hypertrophy [7,8]. However, no information is
available regarding the possible influence of the relationship
between these molecules on the prognosis of patients with CAD.
We have studied 704 patients with CAD in order to assess
whether plasma levels of calcidiol (a vitamin D metabolite) and
FGF-23 are related to the incidence of adverse outcomes, and the
potential influence of their relationship on the prognosis.
Methods
Patients
The BACS & BAMI (Biomarkers in Acute Coronary Syndrome
& Biomarkers in Acute Myocardial Infarction) studies included
patients admitted to four hospitals in Madrid with either non-ST
elevation acute coronary syndrome (NSTEACS) or ST-elevation
myocardial infarction (STEMI). NSTEACS was defined as rest
angina lasting more than 20 minutes in the previous 24 hours, or
new-onset class III-IV angina, along with transient ST depression
or T wave inversion in the electrocardiogram considered
diagnostic by the attending cardiologist and/or troponin elevation.
STEMI was defined as symptoms compatible with angina lasting
more than 20 minutes and ST elevation in two adjacent leads in
the electrocardiogram without response to nitroglycerin, and
troponin elevation. Exclusion criteria were: age over 85 years,
coexistence of other significant cardiac disorders except left
ventricular hypertrophy secondary to hypertension, coexistence
of any illness or toxic habits that could limit patient survival,
impossibility to perform revascularization when indicated, and
subjects in whom follow-up was not possible. In order to avoid
variability of findings due to an excessive heterogeneity in the
intervals between the acute event and blood extraction, the
investigators agreed to exclude patients that were not clinically
stable the sixth day after the index event.
In addition to plasma extraction at discharge, a second plasma
sample was obtained between six and twelve months later, when
the patients were stable. The present paper is a sub-study of BACS
& BAMI studies, and reports data from the clinical and analytic
findings obtained at the moment of this extraction, relating them
to subsequent follow-up.
Between July 2006 and April 2010, 1,898 patients were
discharged from the study hospitals with a diagnosis of NSTEACS
or STEMI. Eight hundred thirty-eight patients were included in
the study. The remaining patients were not included due to the
following: age over 85 years (17.3%), presence of disorders or toxic
habits limiting survival (29.0%), impossibility to perform cardiac
revascularization (14.5%), coexistence of other significant cardi-
opathy (6.8%), impossibility to perform follow-up (12.0%), clinical
instability beyond the sixth day after the index event (9.1%),
refusal to participate in the study (2.0%), and impossibility of the
investigators to include them (9.3%). Of the 838 patients included
in the acute phase, 7 died before the second visit, and 709 had
adequate plasma samples withdrawn six to twelve months after
being discharged. These patients were included in the present sub-
study. Plasma extraction and baseline visits took place between
January 2007 and February 2011. Last follow-up visits were
carried out on May 2012.
Ethics Statement
The research protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinky as reflected in a priori approval by
the human research committees of the institutions participating in
this study: Fundacio´n Jime´nez Dı´az, Hospital Fundacio´n Alcor-
co´n, Hospital de Fuenlabrada y Hospital Universitario de
Mo´stoles. All patients signed informed consent documents.
Study Design
At baseline, clinical variables were recorded and twelve-hour
fasting venous blood samples were withdrawn and collected in
EDTA. Blood samples were centrifuged at 2,500 g for 10 minutes
and plasma was stored at 280uC. Patients were seen every year at
their hospital. At the end of follow-up (maximum 4.6 years) the
medical records were reviewed and patient status was confirmed
by telephone contact.
The outcome was the combination of acute ischemic events
(NSTEACS, STEMI, stroke and transient ischemic attack) plus
heart failure and all-cause mortality. NSTEACS and STEMI were
defined as explained above. A past myocardial infarction was
diagnosed in the presence of new pathological Q waves in the
electrocardiogram along with a concordant new myocardial scar
identified either by echocardiography or nuclear magnetic
resonance imaging. Stroke was defined as rapid onset of a
neurologic deficit attributable to a focal vascular cause lasting
more than 24 hours or supported by new cerebral ischemic lesions
at imaging studies. A transient ischemic attack was defined as a
transient stroke with signs and symptoms resolving before 24 hours
without cerebral acute ischemic lesions at imaging techniques.
Heart failure was a clinical diagnosis made in accordance to
practice guidelines [9]. Events were adjudicated by at least two
investigators of the study, along with a neurologist for cerebro-
vascular events. Although all events were recorded for each case,
patients were excluded from the Cox regression analysis after the
first event. Then, although the total number of events is described,
patients that had more than one event were computed only once
for these analyses.
Biomarker and Analytical Studies
Plasma determinations were performed at the laboratory of
Nephrology at the Go´mez-Ulla hospital and at the Biochemistry
Laboratory at Fundacio´n Jime´nez Dı´az. The investigators who
performed the laboratory studies were unaware of clinical data.
Plasma calcidiol levels were quantified by chemiluminescent
immunoassay (CLIA) on the LIAISON XL analyzer (LIAISON
25OH-Vitamin D total Assay DiaSorin, Saluggia, Italy), FGF-23
was measured by an enzyme-linked immunosorbent assay which
recognizes epitopes within the carboxyl-terminal portion of FGF-
23 (Human FGF-23, C-Term, Immutopics Inc, San Clemente,
CA), intact parathormone was analyzed by a second-generation
automated chemiluminescent method (Elecsys 2010 platform,
Roche Diagnostics, Mannheim, Germany), phosphate was deter-
mined by an enzymatic method (Integra 400 analyzer, Roche
Diagnostics, Mannheim, Germany), and high-sensitivity C-reac-
tive protein was assessed by latex-enhanced immunoturbidimetry
(ADVIA 2400 Chemistry System, Siemens, Germany). Lipids,
glucose and creatinine determinations were performed by
standard methods (ADVIA 2400 Chemistry System, Siemens,
Germany).
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Table 1. Baseline characteristics of patients.
Patients Without Events (N = 627) Patients with Events (N = 77) P value
Age (yr) 59.0 (51.0–71.0) 72.0 (61.5–77.0) ,0.001
Male sex (%) 76.7 63.6 0.017
Caucasian (%) 97.0 97.4 1.000
Body-mass index (Kg/m2) 28.4 (25.7–30.8) 28.6 (25.7–34.1) 0.134
Diabetes (%) 22.0 33.8 0.031
Present smoker (%) 6.7 5.2 0.808
Hypertension (%) 62.4 88.3 ,0.001
Peripheral artery disease (%) 3.3 7.8 0.105
Cerebrovascular events (%) 3.0 6.5 0.170
Previous CABG (%) 7.3 16.9 0.008
Previous PCI (%) 78.1 77.9 1.000
Ejection fraction,40% (%) 11.6 13.0 0.016
Past or present Atrial fibrillation (%) 3.3 16.9 ,0.001
Aspirin (%) 92.7 85.7 0.045
Clopidogrel (%) 68.6 61.0 0.197
Acenocumarol (%) 4.6 15.6 0.001
Statins (%) 88.7 79.2 0.026
Oral antidiabetic drugs (%) 17.4 20.8 0.434
Insulin (%) 5.4 14.3 0.006
ACEI/ARB (%) 71.0 64.9 0.291
Aldosterone receptor blockers 5.1 11.7 0.034
Betablockers (%) 77.2 70.1 0.200
Verapamil (%) 0.5 0.0 1.000
Diltiazem (%) 2.7 7.8 0.031
Dihydropyridines (%) 15.9 22.1 0.193
Diuretics (%) 17.7 32.5 0.003
Digoxin (%) 0.3 1.3 0.294
DATA FROM LAST ACS
STEMI/NSTEACS (%) 39.6/60.4 31.2/68.8 0.173
Number of vessels diseased 1.3560.80 1.5760.83 0.022
Left main disease (%) 3.8 5.2 0.804
Revascularization (%) 80.5 72.7 0.136
Type of revascularization 0.331
CABG (%) 4.9 5.2
Drug-eluting stent (%) 47.6 36.4
Conventional stent (%) 25.8 29.9
Balloon angioplasty (%) 2.1 1.3
No revascularization (%) 19.5 27.3
Complete revascularization (%) 67.3 49.1 0.007
ANALYTICAL DATA
LDL cholesterol (mg/dl) 82.7624.2 86.7635.2 0.335
HDL cholesterol (mg/dl) 43.7610.7 45.2612.2 0.250
Non-HDL colesterol (mg/dl) 108.3629.7 114.0639.6 0.224
Triglycerides (mg/dl) 130.4684.7 136.8666.7 0.522
Glycemia (mg/dl) 109.0633.3 110.2646.9 0.786
GFR (MDRD) (ml/min/1.73 m2) 73.4 (61.9–84.1) 64.1 (48.2–79.2) ,0.001
HS C-reactive protein (mg/L) 4.4169.73 5.2069.11 0.499
Calcidiol (ng/ml) 19.0 (14.0–24.7) 16.5 (10.6–23.4) 0.003
Calcidiol range 0.004
#10 ng/ml 9.5 22.1
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Statistical Analysis
Quantitative data following a normal distribution are presented
as mean6standard deviation (SD), those not normally distributed
are displayed as median (interquartile range), and qualitative
variables are presented as percentages. Also, correlations between
quantitative variables were assessed with the Spearman’s rho
coefficient (r).
Given the existence of four clinically relevant categories [10],
calcidiol levels were assessed using these categories instead of
studying it as a continuous variable: 0.00–10.00 ng/ml (severe
deficiency), 10.01–20.00 ng/ml (moderate deficiency), 20.01–
30.00 ng/ml (insufficiency/suboptimal levels), and higher than
30.00 ng/ml (sufficiency). In univariate analyses, the association of
categories of calcidiol and FGF-23 with the adverse outcome was
summarized by Kaplan-Meier curves. Differences in baseline data
of patients meeting the primary outcome as compared to those
remaining stable were assessed using x2 or Fisher exact test for
qualitative data. For quantitative variables, a Student’s t-test was
performed for those following a normal distribution, and the
Mann-Whitney test was used in those not normally distributed. All
variables that showed significant differences in these tests (Table 1)
were entered into a multivariate Cox model with stepwise forward
selection of variables. In this model, the interaction between
calcidiol and FGF-23 was assessed with an interaction term
defined as the product of those variables dichotomized using the
sample median; statistical significance was assessed with the Wald
test. Given that ‘‘p’’ value for interaction was 0.025, analyses were
repeated in two strata defined by the median of FGF-23.
Analyses were performed with SPSS 19.0 (SPSS Inc., New
York), and were considered significant when ‘‘p’’ was lower than
0.05 (two-tailed).
Results
Baseline Characteristics of the Patients
From the 709 patients included, 5 were lost to follow-up, leaving
a total of 704 for analysis. Age was 61.4612.3 years. Estimated
glomerular filtration rate was 72.0618.0 ml/min1.73 m2 (Modi-
fication of Diet in Renal Disease Method) and 22.4% of patients
had this value below 60 ml/min 1.73 m2. Time from last acute
coronary event was 7.563.0 months. Four patients (0.6%) were
taking vitamin D supplements.
Calcidiol levels were up to 10.0 ng/ml in 10.9% of patients,
10.01–20.00 ng/ml in 46.4%, 20.01–30.0 ng/ml in 32.3% and
higher than 30 ng/dl in 10.4%. Parathormone levels were 59.7
(45.5–77.5) pg/ml, and 30% of the patients displayed increased
levels (higher than 74 pg/ml). Phosphate levels were 3.2 (2.8–
3.5) mg/dl, with 0.9% of cases with values above 4.5 mg/dl. FGF-
23 levels were 69.9 (54.5–96.3) RU/ml, with 11.5% of cases above
130 RU/ml.
Clinical Events
Mean follow-up was 2.1560.99 years. Seventy-seven patients
developed the outcome. Of these, 12 suffered two events and 5
developed 3 events. There were 39 NSTEACS, 4 STEMI, 8
strokes, 10 transient ischemic attacks, 16 episodes of heart failure
and 22 deaths. Eight deaths were due to cardiovascular causes,
four to malignancies and one to infection, renal failure, bowel
ischemia, gastrointestinal bleeding and pancreatitis. Five deaths
were of unknown etiology.
Relationship of Calcidiol and FGF-23 Plasma Levels with
Prognosis in the Whole Population
Kaplan-Meier curves showed that prognosis was worse as
plasma calcidiol levels decreased (p = 0.004) (Figure 1, left).
Conversely, progressively increasing levels of FGF-23 were
associated with poorer prognosis (p = 0.004) (Figure 1, right).
Patients that developed the outcome had higher FGF-23 and
parathormone plasma levels but low calcidiol levels and glomer-
ular filtration rate than those who remained stable (Table 1).
Phosphate, high sensitivity C-reactive protein and lipid levels
showed no differences between both groups. In multivariate
analyses, FGF-23 plasma levels and calcidiol categories remained
as independent predictors of outcome, along with age and
hypertension (Table 2).
Influence of the Relationship between Calcidiol and FGF-
23 Levels on Prognosis
To explore this relationship, we divided the population in two
groups according to median FGF-23 levels (69.9 RU/mL).
Kaplan-Meier curves showed that the relationship between the
different calcidiol categories and outcome observed in the whole
population did not hold in patients with FGF-23 levels equal or
below the median (p = 0.763) (Figure 2, left). In contrast, this
association became more evident in the subgroup with FGF-23
levels above the median (p = 0.002) (Figure 2, right).
When Cox multivariate analysis was repeated in patients with
FGF-23 plasma levels above the median, calcidiol categories were
still independent predictors of the outcome (Table 3). However,
Table 1. Cont.
Patients Without Events (N = 627) Patients with Events (N = 77) P value
10.01–20.0 ng/ml 46.3 46.8
20.01–30 ng/ml 33.1 26.0
.30.0 ng/ml 11.1 5.2
FGF-23 (RU/ml) 69.3 (53.9–93.1) 85.0 (61.9–118.2) 0.003
Parathormone (pg/ml) 59.4 (44.4–75.9) 65.1 (48.1–93.0) 0.025
Phosphate (mg/dl) 3.2361.38 3.3560.61 0.489
Categorical variables are presented as percentages, quantitative variables with normal distribution as mean6SD and those not normally distributed as median
(interquartile range).
ACEI: Angiotensin Converting Enzyme Inhibitors; ACS: Acute coronary syndrome; ARB: Angiotensin receptor blockers; CABG: Coronary Artery by-pass graft; FGF-23:
Fibroblast Growth Factor-23; GFR: Glomerular Filtration Rate; HDL: High-density lipoprotein; HS: High-Sensitivity; LDL: Low-density lipoprotein; MDRD: Modification of
diet in renal disease; NSTEACS: Non-ST Elevation Acute Coronary Syndrome; PCI: Percutaneous coronary Intervention; STEMI: ST-Elevation Myocardial Infarction.
doi:10.1371/journal.pone.0095402.t001
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calcidiol was no longer an independent predictor of the outcome
in patients with FGF-23 plasma levels below the median (Table 4).
Relationship between Mineral Metabolism Parameters
and Estimated Glomerular Filtration Rate, Age, Sex and
C-reactive Protein
There was a modest inverse correlation between estimated
glomerular filtration rate and both FGF-23 (r =20.351; p,0.001)
and parathormone (r =20.255; p,0.001). Calcidiol (r = 0.000;
p = 1.000) and phosphate (r =20.034; p = 0.376) were not
correlated with renal function. Similarly, age showed a mild
correlation with FGF-23 (r = 0.209; p,0.001) and parathormone
(r = 0.236; p,0.001), but it did not correlate with calcidiol (r =
20.036; p = 0.343) and phosphate levels (r =20.031; p = 0.420).
Compared to men, women showed lower levels of calcidiol (17.1
[12.3–23.3] versus 19.3 [14.1–24.9] ng/ml; p = 0.003) but higher
FGF-23 (84.6 [65.6–124.2] versus 66.8 [52.5–89.6)] RU/mL; p,
0.001), parathormone (70.4 [52.1–91.2] pg/mL versus 56.9 [43.5–
73.8]; p,0.001) and phosphate (3.4 [3.1–3.8] versus 3.1 [2.8–3.5]
mg/dl; p,0.001).
C-reactive protein showed a mild correlation with FGF-23
(r = 0.159; p,0.001) and calcidiol (r =20.111; p = 0.003), but not
with parathormone (r =20.009; p = 0.814) or phosphate
(r = 0.050; p = 0.191).
By multivariate linear regression analysis we investigated how
much of calcidiol (Table 5) and FGF-23 plasma levels (Table 6)
were explained by age, sex, glomerular filtration rate, and
parathormone, phosphate, and high sensitivity C-reactive protein
plasma levels. The R2 value was 0.121 for calcidiol and 0.187 for
FGF-23 plasma levels, indicating that the variables studied
explained only a low percentage of the variation of these
parameters.
Discussion
This study demonstrates for the first time that the combination
of calcidiol and FGF-23 plasma levels is a strong predictor of
adverse events in patients with CAD.
Our report also shows that the abnormalities of mineral
metabolism are present in a remarkable number of patients with
CAD, even although only one-fifth of them had an estimated
glomerular filtration rate lower than 60 mL/min/1.73 m2. The
presence of these alterations is not merely a marker of decreased
renal function, as the estimated glomerular filtration rate did not
correlate with calcidiol and phosphate and showed only a mild
correlation with FGF-23 and parathormone.
We have also demonstrated that low vitamin D levels were
independently associated with an adverse prognosis in patients
with CAD. These findings are in accordance with several previous
studies. Three meta-analyses, including patients with and without
Figure 1. Kaplan-Meier survival curves showing the differences in outcome in the whole population. Low calcidiol (left) and high FGF-23
(right) plasma levels are associated with a worse prognosis.
doi:10.1371/journal.pone.0095402.g001
Table 2. Multivariable Cox model for the incidence of the outcome in the whole population.
Hazard Ratio 95% CI P value
Lower Upper
Age 1.05 1.03 1.07 ,0.001
Hypertension 2.61 1.22 5.58 0.013
FGF-23 1.13* 1.04* 1.23* 0.005
Calcidiol 0.67 0.48 0.94 0.021
CI: Confidence Interval; FGF-23: Fibroblast Growth Factor-23.
*Increase in hazard ratio per 100 RU/ml.
Calcidiol is assessed as categorical variable. Reference category is: 0.00–10.00 ng/ml.
doi:10.1371/journal.pone.0095402.t002
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cardiovascular disease at baseline, found an inverse association
between circulating 25-hydroxyvitamin D levels and risk of
cardiovascular disease and cardiovascular death [11–13]. Also,
low plasma vitamin levels have been associated with the severity of
CAD [14,15]. On the other hand, high vitamin D levels are
associated with decreased risk of CAD in the general population
[6,16]. In fact, low vitamin D may lead to endothelial dysfunction,
inflammation, activation of the renin-angiotensin system, vascular
smooth muscle cell proliferation and vascular calcification and
myocardial infarction [5,14,17–19]. Very recently, Siasos et al
found that vitamin D deficiency was an independent predictor of
adverse outcome in patients with CAD undergoing coronary
angiography [20]. However, the sample size was lower than that of
the present study, and the other components of mineral
metabolism were not assessed.
Conversely, vitamin D plasma levels failed to predict the
incidence of cardiovascular events and mortality in patients with
stable CAD randomized to two doses of atorvastatin [21]. It was
hypothesized that statins could overcome the vascular damage
related to vitamin D deficiency. However, in our study, most
patients were receiving statins and, in spite of this, calcidiol levels
predicted an adverse outcome.
Calcidiol levels showed a mild correlation with C-reactive
protein and no correlation with estimated glomerular filtration
rate, suggesting that calcidiol levels provide prognostic information
that is unrelated to these factors. Nevertheless, in our patients,
none of these variables were independent predictors of an adverse
prognosis. Indeed, C-reactive protein levels were not different
between both groups at baseline. Although this molecule has been
suggested to be an independent risk predictor, not all the studies
confirm this idea [22]. Regarding glomerular filtration rate,
although patients developing events displayed lower values of this
parameter at baseline, it was also not an independent predictor of
adverse prognosis at multivariate analysis. It seems possible that
calcidiol and also FGF-23 levels are more direct markers of the
abnormalities leading to cardiovascular damage in renal dysfunc-
tion than glomerular filtration rate. Of interest, lipid levels were
not different between patients that met the primary outcome and
those who remained stable. Although the prognostic implication of
this parameter is well known, it is possible that this information is
less useful in patients on secondary prevention as, in this setting,
intensive statin therapy is advised, and lipid levels become more
homogeneous and thus may have less ability to discriminate
prognosis.
A second finding of this study was that high FGF-23 plasma
levels were also a strong independent predictor of adverse
prognosis. Plasma levels of this phosphaturic hormone gradually
rise in chronic kidney disease to prevent hyperphosphatemia.
FGF-23 is also a potent inhibitor of parathormone secretion and
reduces vitamin D levels trough decreased production and
Figure 2. Kaplan-Meier survival curves showing the differences in outcome as predicted by calcidiol in population subgroups
according to FGF-23 plasma levels. In patients with FGF-23 lower than or equal to the median (69.9 RU/mL), calcidiol plasma levels are no longer
associated with prognosis (left). However, calcidiol levels are still strongly associated with a worse prognosis in the subgroup with FGF-23 levels
above the median (right).
doi:10.1371/journal.pone.0095402.g002
Table 3. Multivariable Cox model for the incidence of the outcome in patients with FGF-23 plasma levels higher than the median.
Hazard Ratio 95% CI P value
Lower Upper
Age 1.06 1.03 1.09 ,0.001
Hypertension 3.60 1.10 11.78 0.011
Calcidiol 0.50 0.31 0.80 0.003
CI: Confidence Interval.
Calcidiol is assessed as categorical variable. Reference category is: 0.00–10.00 ng/ml.
doi:10.1371/journal.pone.0095402.t003
Vitamin D, FGF-23 and Outcomes in Coronary Artery Disease
PLOS ONE | www.plosone.org 6 April 2014 | Volume 9 | Issue 4 | e95402
enhanced catabolism [2,23]. High FGF-23 levels are associated
with an enhanced risk of mortality in patients undergoing
hemodialysis [24]. Although these levels could reflect the risk
associated with vitamin D deficiency and hyperparathyroidism, it
has been hypothesized that this factor itself could contribute to
cardiovascular disease. In this sense, FGF-23 has been related with
endothelial dysfunction, increased arterial stiffness, high athero-
sclerosis burden in the community, vascular calcification, left
ventricular hypertrophy, and progression of renal disease [3,25–
29].
Several studies have reported different results about the
relationship between FGF-23 and CAD. In the Uppsala Longi-
tudinal Study of Adult Men (ULSAM), high FGF-23 blood levels
were also associated with increased risk of cardiovascular mortality
in the community, even after adjustment for glomerular filtration
rate [28]. On the other hand, no relationship between cardiovas-
cular risk and FGF-23, parathormone, and phosphate plasma
levels was found in men without cardiovascular disease at baseline
after adjusting for 25-hydroxyvitamin D levels and clinical data in
the Health Professionals Follow-up Study (HPFS) [30]. However,
the profile of these populations was quite different. In the ULSAM
study, 27% of cases had a previous diagnosis of cardiovascular
disease, glomerular filtration rate was lower, and age and FGF-23
plasma levels were higher than in the HPFS study. Then, it seems
that FGF-23 may be specially effective as a prognostic marker in
populations at high risk of adverse outcomes. In this regard, our
study included population at high risk, with a previous diagnosis of
CAD and a glomerular filtration rate more similar to that of
patients from the ULSAM study. Also, our patients had lower
vitamin D and high FGF-23, PTH and phosphate plasma levels
than those of the HPFS study. Finally, the Heart and Soul Study
showed a relationship between FGF-23 and cardiovascular risk
patients with CAD and average renal function [4]. The present
study extends this observation investigating also the relationship
between the prognostic value of FGF-23 and vitamin D plasma
levels.
The most relevant finding of this study was that the ability of
low calcidiol levels to predict an adverse outcome was limited to
those cases where FGF-23 was higher than the median, with this
predictive power disappearing when FGF-23 was equal or below
these levels. Of interest, the prognostic information provided by
both metabolites was independent as evidenced by the multivar-
iate analysis. This finding is important, since a wide collection of
clinical and analytical data have been assessed, including high
sensitivity C-reactive protein and lipid levels.
As explained, FGF-23 contributes to decrease vitamin D levels.
A recent work has shown that predialysis patients with high FGF-
23 and low vitamin D levels have higher probability of doubling
serum creatinine or initiating dialysis [31]. Similarly, a study
carried out in patients with advanced chronic kidney disease
showed that low plasma vitamin D levels were associated with
death and initiation of long-term dialysis, but FGF-23 levels
attenuated this relationship [32]. However, this is the first time
that this association has been found related to an adverse clinical
outcome in patients with CAD. This relationship may be
important in understanding why some studies have found that
low vitamin D levels are not associated with increased cardiovas-
cular risk [21]. It may also be relevant to explain the controversial
results obtained in studies with vitamin D supplementation [33–
35] and it should be taken into account in the design of future
trials, as the effect of vitamin D could depend on FGF-23 plasma
levels. Furthermore, as vitamin D supplementation may increase
FGF-23 levels [36], monitoring this factor could be of interest in
future clinical trials. Finally, both calcidiol and FGF-23 plasma
levels could be considered in the design of future risk scales for
patients with CAD.
There are limitations in this study. 1) Urinary albumin was not
measured in our population, so earlier stages of chronic renal
Table 4. Multivariable Cox model for the incidence of the outcome in patients with FGF-23 plasma levels equal or lower than the
median.
Hazard Ratio 95% CI P value
Lower Upper
Age 1.04 1.01 1.07 0.023
Hypertension 2.54 0.92 6.98 0.052
Calcidiol 1.03 0.62 1.71 0.904
CI: Confidence Interval.
Calcidiol is assessed as categorical variable. Reference category is: 0.00–10.00 ng/ml.
doi:10.1371/journal.pone.0095402.t004
Table 5. Multivariate linear regression analysis assessing the relationship of calcidiol with other variables studied.
b coefficient 95% CI P value
Lower Upper
Intercept 54.69 47.26 62.11 ,0.001
Log PTH 27.47 28.99 25.96 ,0.001
GFR 20.06 20.09 20.02 0.001
Log hs-CRP 20.67 21.16 20.18 0.007
R2 = 0.121.
Age, sex, Glomerular filtration rate (GFR), Log parathormone (PTH), Phosphate and Log high sensitivity C-reactive protein (hs-CRP) were assessed in the model.
doi:10.1371/journal.pone.0095402.t005
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disease could have gone undetected. 2) Excluding patients not
clinically stable during the first days after the index event could
introduce a certain bias, because these patients would probably
have a worse prognosis. Nevertheless, only nine percent of cases
were excluded for this reason.
Conclusions
Low calcidiol plasma levels are an independent predictor of
adverse outcome in patients with stable CAD who have high FGF-
23 levels. Assessment of both, calcidiol and FGF-23 plasma
concentration could be of interest in risk prediction in these
patients.
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